Topical Pain Relief, Reimagined.
FoamaDerm® is a clinically tested, propellant-free foam base for compounded topical diclofenac — delivering superior drug release at lower concentrations, with better patient compliance.
Not all compounding bases are equal. FoamaDerm® was developed by pharmaceutical scientists who saw firsthand the limitations of conventional bases — greasy textures, poor absorption, and low patient adherence. We built something better.
The 5 Key Advantages
1. Patient Tested Efficacy
The effectiveness of 2% diclofenac in FoamaDerm® has been clinically evaluated at the University of Alberta in patients with chronic pain — with documented improvements in pain scores and function. Read the published study
2. Superior Drug Release Profile
Studies show that diclofenac releases faster and more completely from FoamaDerm® than from conventional bases and brand-name products — meaning effective treatment at up to 3%, where other bases require 5–10%. Read the article
4. Enhanced Skin Penetration
Formulated using nanotechnology, FoamaDerm® optimizes the delivery of active ingredients through the skin barrier, improving therapeutics outcomes without increasing concentration.
5. Simple to Compound
No solvents. No levigating agents. No special equipment. Just add the active ingredient, gently swirl, and dispense. Compounding is complete within 15–20 minutes.
3. Better Patient Compliance
FoamaDerm® is water-based, non-greasy, and leaves no residue on skin or clothing. Patients apply it comfortably at any time of day — which means they actually use it.
Patient demographics and their treatment response to 2% diclofenac in FoamaDerm®. (Ref: adapted from BMC Res Notes 13, 285, 2020)
